242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive

• Tyler Curiel,
• Matthew Hart,
• Yilun Deng,
• Ryan Reyes,
• Myrna Garcia,
• Haiyan Bai,
• Alvaro Padron,
• Harshita Gupta,
• Niannian Ji,
• Anand Kornepati,
• Clare Murray,
• Srikanth Polusani,
• Suresh Kari

Affiliations

Tyler Curiel

UT Health San Antonio, San Antonio, TX, USA

Matthew Hart

University of Texas Health San Antonio, San Antonio, TX, USA

Yilun Deng

UT Health San Antonio, San Antonio, TX, USA

Ryan Reyes

UT Health San Antonio, San Antonio, TX, USA

Myrna Garcia

UT Health San Antonio, San Antonio, TX, USA

Haiyan Bai

1UT Health San Antonio, San Antonio, TX, USA

Alvaro Padron

1UT Health San Antonio, San Antonio, TX, USA

Harshita Gupta

UT Health San Antonio, San Antonio, TX, USA

Niannian Ji

Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, USA

Anand Kornepati

UT Health San Antonio, San Antonio, TX, USA

Clare Murray

Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK

Srikanth Polusani

University of Texas Health San Antonio, San Antonio, TX, USA

Suresh Kari

University of Texas Health San Antonio, San Antonio, TX, USA